Engineering immune cells to enhance their disease-fighting abilities
Signaling via MHC: engineering immune cells with new capabilities
This study is exploring a new way to help your immune system's T cells better recognize and fight diseases like cancer and autoimmune disorders, which could lead to more effective treatments for you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10472922 on NIH RePORTER |
What this research studies
This research focuses on improving the way T cells, a crucial part of the immune system, recognize and respond to diseases like cancer and autoimmune disorders. By modifying Major Histocompatibility Complex (MHC) molecules to include signaling capabilities, the researchers aim to create a two-way communication system that enhances T cell activation and function. This innovative approach could lead to more effective treatments by enabling T cells to better target and eliminate diseased cells. Patients may benefit from new therapies that harness their immune system more effectively against various diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with cancers or autoimmune disorders who may benefit from enhanced immune therapies.
Not a fit: Patients with non-immunological conditions or those who do not have a functioning immune system may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking therapies that significantly improve the immune response against cancers and autoimmune diseases.
How similar studies have performed: Other research has shown promising results in engineering immune cells for enhanced functionality, indicating that this approach has potential for success.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Joglekar, Alok — University of Pittsburgh at Pittsburgh
- Study coordinator: Joglekar, Alok
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.